Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

Related Articles by Review for PubMed (Select 21960186)

1.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
2.

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Review.

PMID:
19325452
3.

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.

Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. Review.

PMID:
19325447
4.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Duggan ST.

Drugs. 2010 Oct 22;70(15):1973-86. doi: 10.2165/11205110-000000000-00000. Review.

PMID:
20883054
5.

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Plosker GL.

Paediatr Drugs. 2013 Oct;15(5):403-23. doi: 10.1007/s40272-013-0047-z. Review.

PMID:
24030738
6.

Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants.

Lagos R, Munoz A, Levine MM, Watson W, Chang I, Paradiso P.

Vaccine. 2009 Apr 14;27(17):2299-305. doi: 10.1016/j.vaccine.2009.02.022. Epub 2009 Feb 13. Review.

PMID:
19428843
7.

Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.

Sucher AJ, Chahine EB, Nelson M, Sucher BJ.

Ann Pharmacother. 2011 Dec;45(12):1516-24. doi: 10.1345/aph.1Q347. Epub 2011 Nov 1. Review.

PMID:
22045904
8.

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29. doi: 10.1097/INF.0000000000000079. Review.

9.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

PMID:
24083785
10.
11.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.

Sanford M.

Drugs. 2012 Jun 18;72(9):1243-55. doi: 10.2165/11209330-000000000-00000. Review.

PMID:
22686616
12.

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

Gruber WC, Scott DA, Emini EA.

Ann N Y Acad Sci. 2012 Aug;1263:15-26. doi: 10.1111/j.1749-6632.2012.06673.x. Epub 2012 Jul 25. Review.

PMID:
22830997
13.

Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience.

Reynolds DL, Vidor E.

Expert Rev Vaccines. 2014 Aug;13(8):943-68. doi: 10.1586/14760584.2014.933674. Epub 2014 Jul 2. Review.

PMID:
24985159
14.

Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis.

Rückinger S, Dagan R, Albers L, Schönberger K, von Kries R.

Vaccine. 2011 Dec 6;29(52):9600-6. doi: 10.1016/j.vaccine.2011.09.011. Epub 2011 Sep 18. Review.

PMID:
21933696
15.

The safety advantages of pentavalent vaccines.

Merchant N, Waldrop J.

Nurse Pract. 2012 Apr 15;37(4):48-53. doi: 10.1097/01.NPR.0000412895.12310.9d. Review.

PMID:
22430930
16.

Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.

Madhi SA, Cohen C, von Gottberg A.

Vaccine. 2012 Sep 7;30 Suppl 3:C21-7. doi: 10.1016/j.vaccine.2012.05.055. Review.

PMID:
22939016
17.

The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.

Park DE, Johnson TS, Nonyane BA, Chandir S, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL, Deloria Knoll M.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S130-9. doi: 10.1097/INF.0000000000000081. Review.

18.

Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

Durando P, Alicino C, De Florentiis D, Martini M, Icardi G.

J Prev Med Hyg. 2012 Jun;53(2):68-77. Review.

PMID:
23240163
19.

A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children.

Grijalva CG, Pelton SI.

Curr Opin Pediatr. 2011 Feb;23(1):98-104. doi: 10.1097/MOP.0b013e328341d1f5. Review.

20.

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis.

Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM.

Vaccine. 2013 Nov 4;31(46):5349-58. doi: 10.1016/j.vaccine.2013.09.008. Epub 2013 Sep 19. Review.

PMID:
24055349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk